The role of brigatinib in crizotinib-resistant non-small cell lung cancer

Overview of attention for article published in Cancer Management and Research, January 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#36 of 2,014)
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 1 news outlet
policy: 2 policy sources

twitter: 3 X users
reddit: 1 Redditor

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 38 Mendeley

Summary News Policy documents X Reddit Dimensions citations

So far, Altmetric has seen 1 news story.

ASCO Reading Room | Is Brigatinib Still an A-Lister in ALK-Positive NSCLC?

MedPage Today, 10 Nov 2018

The ongoing ALTA trials have made brigatinib (Alunbrig) a marquee name in ALK-positive non-small cell lung cancer (NSCLC)…